Enlivex Therapeutics Ltd.
NASDAQ:ENLVBiotechnology
Healthcare
$4.26 +2.67%
+$0.19 today
- Market cap
- $71.70M
- Beta
- 1.52
- P/E (TTM)
- 0.0
- EPS (TTM)
- $407.81
52W Low $6.42High $31.50
Volume 0.06M
Average 0.44M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$10.42M
FY 2025 · Annual
Investing Cash Flow
-$1.32M
FY 2025 · Annual
Financing Cash Flow
$10.38M
FY 2025 · Annual
+60.8% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (14.47M) | (31.06M) | (29.07M) | (15.01M) | 1.24B |
| Depreciation & Amortization | 546K | 777K | 835K | 545K | 332K |
| Deferred Income Tax | (5.59M) | 0 | 0 | 0 | 382.65M |
| Stock-Based Compensation | 2.91M | 2.71M | 1.95M | 2.07M | 1.78M |
| Change in Working Capital | (1.36M) | 804K | (1.82M) | (1.22M) | 815K |
| Accounts Receivables | (1.25M) | 278K | 608K | 433K | (3.05M) |
| Inventory | 1.25M | (278K) | 0 | 0 | 0 |
| Accounts Payables | 442K | 1.17M | (1.12M) | (16K) | 3M |
| Other Working Capital | (1.8M) | (364K) | (1.31M) | (1.64M) | 869K |
| Other Non-Cash Items | 413K | 2.81M | 4.58M | 614K | (1.63B) |
| Operating Cash Flow | (17.54M) | (23.95M) | (23.52M) | (13.01M) | (10.42M) |
| Capital Expenditures | (1.63M) | (8.12M) | (236K) | (103K) | (68K) |
| Acquisitions (Net) | (20.03M) | (9.71M) | 0 | 0 | 1.38M |
| Purchases of Investments | (104.42M) | (1.61M) | (26.17M) | (32.37M) | (24.5M) |
| Sales of Investments | 67.63M | 72.25M | 301K | 39.24M | 41.37M |
| Other Investing Activities | 20.03M | 9.71M | 133K | 2.29M | 0 |
| Investing Cash Flow | (38.41M) | 62.52M | (25.97M) | 9.06M | (1.32M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 53.17M | 150K | 360K | 6.45M | 10.38M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 7.81M | 0 | 0 | 2K | 0 |
| Financing Cash Flow | 60.98M | 150K | 360K | 6.45M | 10.38M |
| Effect of Forex Changes | (408K) | (91K) | 0 | 0 | (49K) |
| Net Change in Cash | 4.62M | 38.72M | (49.13M) | 2.51M | (1.41M) |
| Free Cash Flow | (19.17M) | (32.08M) | (23.76M) | (13.11M) | (10.48M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income$1.2B
+ D&A$332.0K
+ Stock-Based Comp$1.8M
+ Deferred Tax$382.6M
+ Working Capital$815.0K
- Other Non-Cash-$1.6B
= Operating Cash Flow-$10.4M
- Capex-$68.0K
= Free Cash Flow-$10.5M
Analysis
FY2025 free cash flow is -$10.5M. FCF conversion is -0.8% of net income. Operating cash flow was -$10.4M, with capex of -$68.0K. The largest bridge item is Other Non-Cash at -$1.6B.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 6-K | 6-K filing | Jul 20, 2026 | |
| 6-K | 6-K filing | Jul 13, 2026 | |
| 6-K | 6-K filing | Jul 7, 2026 | |
| 6-K | 6-K filing | Jun 24, 2026 | |
| 6-K | 6-K filing | Jun 22, 2026 |
Does ENLV generate free cash flow?
Enlivex Therapeutics Ltd. (ENLV) generated -$10.48M of free cash flow in fiscal 2025.
How much operating cash flow does ENLV produce?
Operating cash flow was -$10.42M, before capital expenditures of $68,000.00.
Continue the stock analysis
Jump to another research area for this company.